BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 18094400)

  • 1. Src continues aging: current and future clinical directions.
    Kopetz S; Shah AN; Gallick GE
    Clin Cancer Res; 2007 Dec; 13(24):7232-6. PubMed ID: 18094400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J
    Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Src, chemoresistance and epithelial to mesenchymal transition: are they related?
    Shah AN; Gallick GE
    Anticancer Drugs; 2007 Apr; 18(4):371-5. PubMed ID: 17351389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.
    Mayer EL; Krop IE
    Clin Cancer Res; 2010 Jul; 16(14):3526-32. PubMed ID: 20634194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Issues and progress with protein kinase inhibitors for cancer treatment.
    Dancey J; Sausville EA
    Nat Rev Drug Discov; 2003 Apr; 2(4):296-313. PubMed ID: 12669029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors.
    Alvarez RH; Kantarjian HM; Cortes JE
    Cancer; 2006 Oct; 107(8):1918-29. PubMed ID: 16986126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors in lymphoma and solid malignancies.
    Rasheed W; Bishton M; Johnstone RW; Prince HM
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):413-32. PubMed ID: 18366289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
    Toschi L; Jänne PA
    Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational combinations using HDAC inhibitors.
    Bots M; Johnstone RW
    Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Src inhibitors in lung cancer: current status and future directions.
    Rothschild SI; Gautschi O; Haura EB; Johnson FM
    Clin Lung Cancer; 2010 Jul; 11(4):238-42. PubMed ID: 20630825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Src tyrosine kinase substrate binding site inhibitors.
    Ye G; Tiwari R; Parang K
    Curr Opin Investig Drugs; 2008 Jun; 9(6):605-13. PubMed ID: 18516760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
    Ischenko I; Camaj P; Seeliger H; Kleespies A; Guba M; De Toni EN; Schwarz B; Graeb C; Eichhorn ME; Jauch KW; Bruns CJ
    Oncogene; 2008 Dec; 27(57):7212-22. PubMed ID: 18794807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
    Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
    Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives on farnesyl transferase inhibitors in cancer therapy.
    Mazieres J; Pradines A; Favre G
    Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRC as a potential therapeutic target in solid tumor oncology.
    Gallick GE
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):435-7. PubMed ID: 16163218
    [No Abstract]   [Full Text] [Related]  

  • 17. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
    Dal Lago L; D'Hondt V; Awada A
    Oncologist; 2008 Aug; 13(8):845-58. PubMed ID: 18695262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting protein kinases in cancer therapy: a success?
    Pearson MA; Fabbro D
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1113-24. PubMed ID: 15606337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?
    de Jonge MJ; Verweij J
    Eur J Cancer; 2006 Jul; 42(10):1351-6. PubMed ID: 16740386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.